Bloomberg News

Elan Reaffirms Full-Year Guidance on Tysabri Perfomance

October 27, 2011

Oct. 27 (Bloomberg) -- Elan Elan Corp. said “based on the strong performance of Tysabri year-to-date, we are re-affirming our full year guidance and now expect revenues from our BioNeurology business to exceed $1 billion this year.”

To contact the editor responsible for this story: Dara Doyle at

We Almost Lost the Nasdaq

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

blog comments powered by Disqus